Michael C Forrest

US Patent:

20040242459, Dec 2, 2004

Filed:

Dec 9, 2003

Appl. No.:

10/480363

Inventors:

Michael Forrest - Shrewsbury NJ, US
Joel Berger - Hoboken NJ, US
David Moller - Bedminister NJ, US
Samuel Wright - Westfield NJ, US

International Classification:

A61K038/17

US Classification:

514/002000

Abstract:

A method for treating, controlling, preventing or reducing the risk of contracting an inflammatory disease or condition in a mammalian patient, comprises the steps of (1) selecting a patient in need thereof, and (2) treating the patient with a therapeutically effective amount of a composition comprising a PPAR- agonist. Inflammatory diseases that may be treated by this method include but are not limited to rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, degenerative joint disease, one or more connective tissue diseases, ankylosing spondylitis, and bursitis.

US Patent:

20050027555, Feb 3, 2005

Filed:

Jul 26, 2004

Appl. No.:

10/899536

Inventors:

Michael Forrest - North Reading MA, US
David Schneider - Weston MA, US

International Classification:

G06F017/60
B02C001/00
B28B003/06

US Classification:

705001000, 264140000, 264916000

Abstract:

A closed-loop control system for recycling products, such as food service ware. The system provides a “pure” stream of the products without major contaminants, which facilitates efficient re-fabrication of the product. The system includes collecting the used product from a selected group of users, isolating the used product from other waste, and delivering the product to a reprocessing center. The used product is washed and pelletized to form recycled pellets, which are combined with virgin pellets in ratios conforming with FDA regulations, to produce new recycled products. These new products are then sold back to the group of users, thus maintaining the system in a closed-loop. The recycled products may include plastic materials, such as polystyrene, polyethylene terephthalate, polypropylene, or high density polyethylene. When any of the above-mentioned plastic materials are in their expanded foam state, the system may be more economically feasible to operate. The group of users may include institutions such as school systems and food management services.

US Patent:

20050070506, Mar 31, 2005

Filed:

Jan 14, 2003

Appl. No.:

10/501176

Inventors:

George Doherty - Superior NJ, US
Michael Forrest - Shrewsbury NJ, US
Richard Hajdu - Old Bridge NJ, US
Jeffrey Hale - Westfield NJ, US
Li Zhen - Scotch Plains NJ, US
Susanne Mandala - Scotch Plains NJ, US
Sander Mills - Scotch Plains NJ, US
Hugh Rosen - Springfield NJ, US
Edward Scolnick - Wynnewood PA, US

International Classification:

A61K031/66

US Classification:

514114000

Abstract:

The present invention encompasses a method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor, said compound administered in an amount effective for treating said immunoregulatory abnormality. Pharmaceutical compositions are included. The invention also encompasses a method of identifying candidate compounds that are agonists of the S1P1/Edg1 receptor and which possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor. The invention further encompasses a method of treating a respiratory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said respiratory disease or condition, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor.

US Patent:

20080194548, Aug 14, 2008

Filed:

Jan 5, 2006

Appl. No.:

11/794857

Inventors:

Michael J. Forrest - Shrewsbury NJ, US
Julie A. DeMartino - Westfield NJ, US
Michelle R. Flicker - Bridgewater NJ, US
Augustin Melian - Woodcliff Lake NJ, US
Samina Kanwar - Hoboken NJ, US
Gary J. Romano - Wynnewood PA, US

International Classification:

A61K 31/536
A61K 31/4375
A61K 31/351
A61K 31/40
A61P 11/00
A61P 9/10

US Classification:

5142305, 514300, 514460, 514423

Abstract:

A combination of a CCR2 antagonist and a statin is useful in the treatment and or prevention of inflammatory and other disorders, and methods of treating inflammatory and other disorders using a combination of a CCR2 antagonist and a statin.